ELITE PHARMACEUTICALS INC /NV/ 8-K

What Happened

• On February 17, 2026, Elite Pharmaceuticals, Inc. (ELTP) filed its quarterly report on Form 10-Q for the quarter ended December 31, 2025 and issued a press release summarizing its quarterly results (press release furnished as Exhibit 99.1). The company announced a conference call for investors and shareholders on Wednesday, February 18, 2026 at 11:30 AM Eastern Standard Time to provide a business update and answer pre-submitted questions.

Key Details

• Form 10-Q covering the quarter ended December 31, 2025 was filed on Feb 17, 2026 and a related press release was furnished (Exhibit 99.1).
• Conference call: Feb 18, 2026 at 11:30 AM EST; domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840.
• Investors can submit questions to dianne@elitepharma.com; financial questions were due by 7:00 PM EST on Feb 17, 2026.
• Audio replay is available online: https://elite.irpass.com/events_presentations. The company notes the disclosure is furnished under Regulation FD and is not being “filed” for purposes of Section 18 liability.

Why It Matters

• Filing the Form 10-Q and issuing a press release gives investors access to Elite’s latest quarterly results and financial condition—key inputs for evaluating near-term performance (earnings, revenue and other metrics are in the 10-Q/press release).
• The scheduled conference call and Q&A opportunity allow shareholders to hear management’s commentary and ask direct questions about results and business outlook.
• The Regulation FD/Section 18 note means the press release is furnished for disclosure purposes but is not treated as a “filed” document for certain legal liabilities.